Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

venetoclax 28Cytarabine 25Azacitidine 23Specimen Handling 21fludarabine 15Biopsy 13Injections 12Daunorubicin 11Cyclophosphamide 11fludarabine phosphate 10decitabine and cedazuridine drug combination 9Whole-Body Irradiation 9CPX-351 8Mycophenolic Acid 7Idarubicin 7Granulocyte Colony-Stimulating Factor 7Gemtuzumab 7ivosidenib 6Tacrolimus 6Stem Cell Transplantation 6Filgrastim 6Busulfan 6enasidenib 5X-Rays 5Melphalan 5Etoposide 5Decitabine 5Cyclosporine 5ruxolitinib 4olutasidenib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × TAK-243 × 30 days × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡